{"id":"liquid-mepolizumab","safety":{"commonSideEffects":[{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Upper respiratory tract infections"},{"rate":null,"effect":"Pyrexia"}]},"_chembl":{"chemblId":"CHEMBL2108429","moleculeType":"Antibody"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Mepolizumab targets IL-5, a key cytokine involved in eosinophil development, recruitment, and survival. By neutralizing IL-5, the drug reduces circulating and tissue eosinophil levels, thereby decreasing eosinophil-mediated inflammation. This mechanism is particularly effective in conditions characterized by eosinophilic inflammation, such as severe eosinophilic asthma and eosinophilic granulomatosis with polyangiitis (EGPA).","oneSentence":"Mepolizumab is a monoclonal antibody that binds to interleukin-5 (IL-5) and prevents its interaction with eosinophils, reducing eosinophil production and activation.","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T01:19:03.652Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Severe eosinophilic asthma"},{"name":"Eosinophilic granulomatosis with polyangiitis (EGPA)"},{"name":"Chronic rhinosinusitis with nasal polyps (CRSNP)"}]},"trialDetails":[{"nctId":"NCT04718389","phase":"PHASE3","title":"A Study of GSK3511294 (Depemokimab) Compared With Mepolizumab or Benralizumab in Participants With Severe Asthma With an Eosinophilic Phenotype","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2021-01-26","conditions":"Asthma","enrollment":1719},{"nctId":"NCT04133909","phase":"PHASE3","title":"Mepolizumab as Add-on Treatment IN Participants With COPD Characterized by Frequent Exacerbations and Eosinophil Level","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-10-30","conditions":"Pulmonary Disease, Chronic Obstructive","enrollment":806},{"nctId":"NCT03099096","phase":"PHASE3","title":"Study of Mepolizumab Autoinjector in Asthmatics","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-05-04","conditions":"Asthma","enrollment":159},{"nctId":"NCT03014674","phase":"PHASE3","title":"A Study to Compare the Pharmacokinetics of Mepolizumab as a Liquid Drug in a Safety Syringe or an Autoinjector Versus Lyophilised Drug","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-01-06","conditions":"Asthma","enrollment":246},{"nctId":"NCT03021304","phase":"PHASE3","title":"Study of Mepolizumab Safety Syringe in Asthmatics","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-02-01","conditions":"Asthma","enrollment":56}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":6,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Liquid mepolizumab","genericName":"Liquid mepolizumab","companyName":"GlaxoSmithKline","companyId":"glaxosmithkline","modality":"Biologic","firstApprovalDate":"","aiSummary":"Mepolizumab is a monoclonal antibody that binds to interleukin-5 (IL-5) and prevents its interaction with eosinophils, reducing eosinophil production and activation. Used for Severe eosinophilic asthma, Eosinophilic granulomatosis with polyangiitis (EGPA), Chronic rhinosinusitis with nasal polyps (CRSNP).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}